English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: The present study was conducted to assess the efficacy and safety of bilastine 20 mg and compare the results with that of levocetirizine 5 mg in the treatment of allergic rhinoconjunctivitis. Material and Methods: It was a prospective study conducted in the Department of Ophthalmology and Department of Otorhinolaryngology at a tertiary institute of southern Rajasthan, India during the period of 6 months from September 2019 to February 2020. 100 patients of chronic allergic rhinoconjunctivitis were included in the study, of which 50 were treated with Bilastine 20 mg, and the rest 50 patients were treated with levocetirizine 5 mg. The primary assessment was done by calculating the total symptom score (TSS) before and after the 7th and 14th post-treatment day. Results: The age of the patients ranges from 10 years to 65 years with a mean age of 32±5.2 years. The primary efficacy parameter for assessment was a reduction in total symptom score (TSS). Both bilastine 20 mg and levocetirizine 5 mg significantly reduced the TSS on the 7th and 14th post-treatment days (p-value< 0.001). There was no significant difference between TSS of bilastine and levocetirizine after 7 days (p-value= 0.41) and after 14 days treatment (p-value= 0.68). Adverse events were reported by 10% of patients in the bilastine group and by 38% of patients in the levocetirizine group. Conclusion: Bilastine is a selective H1 antihistamine with good efficacy and excellent safety profile and it is highly recommended to use it as a first-line treatment for allergic rhinoconjunctivitis.

Comparative analysis of efficacy and safety of Bilastine 20 mg and Levocetirizine 5 mg in the treatment of Allergic Rhinoconjunctivitis